

Table 4.1
Counts (Annualized Percentages) of Participants with Self-Reported Outcomes by Age at Enrollment for
MRC Super Cohort Participants¹ Who Did Not Report a Prevalent Condition at Baseline

Data as of: February 19, 2022; Events through February 19, 2022

Outcome	Total	Age at Enrollment			
		50-54	55-59	60-69	70-79
Number of participants	44174	6788	9352	19418	8616
Mean follow-up (months)	189.5	206.1	206.3	190.4	156.4
Angina (hospitalized) ²	3636 (0.55%)	460 (0.41%)	694 (0.45%)	1758 (0.60%)	724 (0.70%)
Diabetes (treated)	8354 (1.27%)	1487 (1.33%)	1922 (1.27%)	3784 (1.31%)	1161 (1.10%)
Hysterectomy	1942 (0.48%)	313 (0.50%)	489 (0.51%)	871 (0.49%)	269 (0.42%)
Osteoarthritis ³	14194 (3.23%)	2502 (2.86%)	3341 (3.01%)	6163 (3.37%)	2188 (3.83%)
Intestinal polyps	10883 (1.68%)	1851 (1.65%)	2597 (1.70%)	4907 (1.72%)	1528 (1.54%)
Lupus ³	811 (0.12%)	132 (0.12%)	181 (0.12%)	370 (0.13%)	128 (0.12%)
Hypertension treated w/pills	16789 (3.54%)	2781 (3.09%)	3790 (3.27%)	7319 (3.65%)	2899 (4.27%)
COPD ⁴	2897 (0.76%)	420 (0.63%)	695 (0.79%)	1432 (0.87%)	350 (0.62%)
Macular degeneration ⁵	5602 (1.07%)	522 (0.57%)	1037 (0.84%)	2802 (1.22%)	1241 (1.58%)
Dementia ⁵	5837 (1.11%)	403 (0.44%)	862 (0.70%)	3014 (1.31%)	1558 (1.99%)
Parkinson's disease ⁵	673 (0.13%)	76 (0.08%)	142 (0.12%)	343 (0.15%)	112 (0.14%)

¹ The MRC Super Cohort includes all WHI Hormone Trial participants and all Non-Hispanic Black/African American and Hispanic/Latina participants (identified from race/ethnicity collected on Form 2 at baseline) from the CT and OS.

² During WHI Extension Study 2005-2010, the outcome was angina with hospitalization for a heart condition that may or may not have been related to the angina.

³ This outcome has not been self-reported on all versions of Form 33 during WHI follow-up. The annualized percentages are corrected for the different amounts of follow-up.

⁴ Data only collected during the WHI Extension Study 2010-2025.

⁵ Data only collected during the WHI Extension Studies 2005-2025.